ACHL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors...

Stats
Šios dienos apimtis	115 040
Vidutinė apimtis	582 007
Rinkos kapitalizacija	38.94M
EPS	$0 ( 2024-05-08 )
Kita pelno data	( $-0.410 ) 2024-08-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.0200 (2.11%)

Achilles Therapeutics plc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CRSP	0.844
SGMO	0.843
GRPN	0.833
NUVL	0.821
ANGI	0.818
FONR	0.806

10 Labiausiai neigiamai susiję koreliacijos
RGLD	-0.876

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Achilles Therapeutics plc Koreliacija - Valiuta/Žaliavos

0.10
( neutral )

0.01
( neutral )

0.00
( neutral )

-0.38
( neutral )

Achilles Therapeutics plc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2023
Pajamos:	$0
Bruto pelnas:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2022
Pajamos:	$0
Bruto pelnas:	$-3.69M (0.00 %)
EPS:	$-1.820

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.36

Financial Reports:

No articles found.

Achilles Therapeutics plc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Achilles Therapeutics plc

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.